Use of in-cycle antimüllerian hormone levels to predict cycle outcome

Andrew S. Blazar*, Geralyn Lambert-Messerlian, Richard Hackett, Stephan Krotz, Sandra A. Carson, Jared C. Robins

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Objective: The goal of this work is to expand the usefulness of antimllerian hormone (AMH) in predicting in vitro fertilization cycle outcome by demonstrating that AMH concentration obtained in an ongoing treatment cycle predicts both oocyte number and pregnancy. Study Design: Serum samples were obtained from 190 in vitro fertilization patients at onset of follicle-stimulating hormone stimulation. These were analyzed retrospectively during a single cycle in which clinicians were blinded to the results. Our major outcome measures were the number of oocytes obtained and ongoing pregnancy. Results: Patients with an initial AMH concentration of >3 ng/mL were found to produce a mean of 19.8 oocytes and had an ongoing pregnancy rate of 60.3%. In contrast, those with AMH values of ≤1 ng/mL yielded a mean of 6.2 oocytes and had an ongoing pregnancy rate of 23.4% (P <.0001 for both). Conclusion: Greater AMH serum concentration strongly predicts an increased number of oocytes and ongoing pregnancy (P ≤.0001).

Original languageEnglish (US)
Pages (from-to)223.e1-223.e5
JournalAmerican journal of obstetrics and gynecology
Issue number3
StatePublished - Sep 2011


  • antimllerian hormone concentration
  • in vitro fertilization treatment outcome

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Use of in-cycle antimüllerian hormone levels to predict cycle outcome'. Together they form a unique fingerprint.

Cite this